^
    Back
    Association details:
    Biomarker:RANBP2-ALK fusion
    Cancer:Soft Tissue Sarcoma
    Drug:Xalkori (crizotinib) (ALK inhibitor)
    Direction:Sensitive
    Evidence:
    Evidence Level:
    Sensitive: C4 – Case Studies
    New
    Source:
    JJCO
    Title:

    A Case Report of Epithelioid Inflammatory Myofibroblastic Sarcoma with RANBP2-ALK Fusion Gene Treated with the ALK Inhibitor, Crizotinib

    Excerpt:
    ...22-year-old Japanese man with a...epithelioid inflammatory myofibroblastic sarcoma with RANBP2-ALK fusion….Subsequent administration of crizotinib, an oral anaplastic lymphoma kinase inhibitor, resulted in tumor shrinkage….Distinguishing epithelioid inflammatory myofibroblastic sarcoma from conventional inflammatory myofibroblastic tumor is important, and crizotinib is a promising treatment for this aggressive tumor.
    DOI:
    10.1093/jjco/hyu069